Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/08/2021 06/09/2021 06/10/2021 06/11/2021 06/14/2021 Date
198.85(c) 209.64(c) 204.94(c) 209.68(c) 207.71(c) Last
3 782 460 4 913 877 3 534 862 2 552 703 11 199 652 Volume
+1.95% +5.43% -2.24% +2.31% -0.94% Change
More quotes
Financials (USD)
Sales 2021 2 163 M - -
Net income 2021 -457 M - -
Net cash position 2021 79,2 M - -
P/E ratio 2021 -27,9x
Yield 2021 -
Sales 2022 5 233 M - -
Net income 2022 2 456 M - -
Net cash position 2022 2 147 M - -
P/E ratio 2022 6,44x
Yield 2022 -
Capitalization 15 385 M 15 385 M -
EV / Sales 2021 7,08x
EV / Sales 2022 2,53x
Nbr of Employees 792
Free-Float 98,7%
More Financials
Company
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline... 
Sector
Biotechnology & Medical Research
Calendar
06/14 | 03:00pmPresentation
More about the company
Ratings of Novavax, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about NOVAVAX, INC.
02:50aJapanese shares track Nasdaq higher, drug makers shine
RE
06/14Japanese shares rally; property developers, growth stocks lead gains
RE
06/14Health Care Shares Edge Lower -- Health Care Roundup
DJ
06/14US Stocks Sneak to Latest Record in Late Push; Nasdaq's Techs Lead, Dow Slips..
MT
06/14CLOSE UPDATE : US Stocks Sneak to Latest Record in Late Push; Nasdaq's Techs Lea..
MT
06/14NOVAVAX  : COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protectio..
PU
06/14NOVAVAX INC  : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/14NOVAVAX  : says efficacy preserved in participants receiving influenza, COVID-19..
RE
06/14NOVAVAX  : Says Simultaneous Inoculation of Influenza Vaccine, COVID-19 Vaccine ..
MT
06/14NOVAVAX  : says vaccine efficacy preserved in participants receiving influenza, ..
RE
06/14NOVAVAX  : Announces Positive Results from First Study of Influenza Vaccine and ..
PR
06/14NOVAVAX  : COVID SCIENCE-Delta variant doubles risk of hospitalization; Novavax ..
RE
06/14Shares Mixed Midday Ahead of Fed's Monetary Policy Meeting
MT
06/14MIDDAY REPORT : US Stocks Mixed Ahead of Fed's Monetary Policy Meeting
MT
06/14European Stocks Close Mixed as Market Expects UK to Delay Full Restrictions E..
MT
More news
News in other languages on NOVAVAX, INC.
12:22aCORONAVIRUS : le point sur la pandémie dans le monde
06/14MÄRKTE USA/Uneinheitlich - Fed-Sitzung im Fokus
06/14WALL STREET STOCK EXCHANGE : Tech trekt de kar op vlak Wall Street
06/14CORONA-BLOG/STUDIE : Zwei Impfstoffdosen verhindern bei Delta-Virusvariante schw..
06/14CORONA-BLOG/WHO  : Coronavirus zirkuliert weltweit schneller als die Impfstoffe
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 249,60 $
Last Close Price 207,71 $
Spread / Highest target 41,5%
Spread / Average Target 20,2%
Spread / Lowest Target -22,5%
EPS Revisions
Managers and Directors
NameTitle
Stanley C. Erck President, Chief Executive Officer & Director
John J. Trizzino CFO, EVP, Chief Commercial & Business Officer
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVAVAX, INC.86.27%15 385
MODERNA, INC.98.54%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.36.45%46 658
CELLTRION, INC.-21.73%32 458
SEAGEN INC.-10.76%28 416